ResearcherActive in the last 2 years
Diana Behrens
Matched on OpenAlex author ID A5039652183. Sources: OpenAlex.
Their work
- Papers
- 13
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 69
2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper
Papers 13
- Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
- EPI-X4, a CXCR4 antagonist inhibits tumor growth in pancreatic cancer and lymphoma models. Co-author DOI 10.1016/j.peptides.2023.171111↗
- Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
- Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. Co-author DOI 10.1186/s13148-024-01623-z↗
- Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
- Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity … Co-author DOI 10.3390/cancers15245753↗
- Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Co-author DOI 10.1038/s41467-021-25921-9↗
- Effective Oncoleaking Treatment of Pancreatic Cancer by Claudin-Targeted Suicide Gene Therapy with Clostridium perfringens Enterotoxin (CPE). Co-author DOI 10.3390/cancers13174393↗
- TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Co-author DOI 10.1038/s41420-020-0246-7↗
- Pancreatic cancer models for translational research. Co-author DOI 10.1016/j.pharmthera.2017.02.013↗
- The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators. Co-author DOI 10.18632/oncotarget.19882↗
- Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-0149↗
- Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Co-author DOI 10.18632/oncotarget.12455↗
Closest collaborators
The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rita Teresa Lawlor · 5 shared papers, 2021–2026 · strength 0.79
- Paper Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expressi… DOI 10.1038/s41467-026-69013-y↗
- Paper Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. DOI 10.1186/s13148-024-01623-z↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Aldo Scarpa Scarpa · 5 shared papers, 2021–2026 · strength 0.79
- Paper Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expressi… DOI 10.1038/s41467-026-69013-y↗
- Paper Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. DOI 10.1186/s13148-024-01623-z↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Jens Thomas Siveke · 4 shared papers, 2020–2026 · strength 0.63
- Paper Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expressi… DOI 10.1038/s41467-026-69013-y↗
- Paper Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. DOI 10.1186/s13148-024-01623-z↗
- Paper Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. DOI 10.1038/s41467-024-54975-8↗
- Sven‐Thorsten Liffers · 3 shared papers, 2020–2026 · strength 0.47
- Paper Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expressi… DOI 10.1038/s41467-026-69013-y↗
- Paper Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. DOI 10.1186/s13148-024-01623-z↗
- Paper TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic c… DOI 10.1038/s41420-020-0246-7↗
- Marija Trajkovic‐Arsic · 3 shared papers, 2020–2026 · strength 0.47
- Paper Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expressi… DOI 10.1038/s41467-026-69013-y↗
- Paper Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. DOI 10.1186/s13148-024-01623-z↗
- Paper TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic c… DOI 10.1038/s41420-020-0246-7↗
- Wolfgang Walther · 3 shared papers, 2017–2023 · strength 0.40
- Paper Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for … DOI 10.3390/cancers15245753↗
- Paper Effective Oncoleaking Treatment of Pancreatic Cancer by Claudin-Targeted Suicide Gene Therapy with Clostridium perfring… DOI 10.3390/cancers13174393↗
- Paper Pancreatic cancer models for translational research. DOI 10.1016/j.pharmthera.2017.02.013↗
- Laura Godfrey · 2 shared papers, 2024–2026 · strength 0.37
- Paper Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expressi… DOI 10.1038/s41467-026-69013-y↗
- Paper Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation. DOI 10.1186/s13148-024-01623-z↗
- Phyllis F. Cheung · 2 shared papers, 2024–2026 · strength 0.36
- Iduna Fichtner · 2 shared papers, 2017–2023 · strength 0.27
- Christopher Heeschen · 2 shared papers, 2021–2023 · strength 0.26
- Juanfei Peng · 1 shared paper, 2026 · strength 0.20
- Markus Vogt · 1 shared paper, 2026 · strength 0.20
- Elmar Wolf · 1 shared paper, 2026 · strength 0.20
- Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.20
- Niklas Krebs · 1 shared paper, 2026 · strength 0.20
- Rickmer Braren · 1 shared paper, 2026 · strength 0.20
- Wolf‐Georg Forssmann · 1 shared paper, 2024 · strength 0.20
- Doaa M. Ali · 1 shared paper, 2024 · strength 0.20
- Martin Reinhold Berger · 1 shared paper, 2024 · strength 0.20
- Micah N. Sagini · 1 shared paper, 2024 · strength 0.20
- Ergül Eyol · 1 shared paper, 2024 · strength 0.20
- Steven A. Johnsen · 1 shared paper, 2024 · strength 0.17
- Barbara Sitek · 1 shared paper, 2024 · strength 0.17
- Francesca Lupo · 1 shared paper, 2024 · strength 0.16
- Rui Fang · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.